期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

超高液相色谱串联质谱测定磷酸肌酸钠中磷酸甲酯

Determination of Trimethyl Phosphate in Creatine Phosphate Sodium by Ultra-high Performance Liquid Chromatography-mass Spectrometry
下载PDF
导出
摘要 采用超高效液相色谱串联三重四级杆质谱法,建立了磷酸肌酸钠中潜在遗传毒性杂质磷酸甲酯含量测定方法。经方法学验证,方法简便、高效、灵敏,可用于磷酸肌酸钠中磷酸甲酯的检测。 Ultra-high performance liquid chromatography-triple quadrupole mass spectrometry was used to establish an ultra-high performance liquid chromatography-mass spectrometry analytical method for determination of trimethyl phosphate in creatine phosphate sodium. After verification, the method was simple, accurately and sensitively, which could be used to determine trimethyl phosphate in creatine phosphate sodium.
作者 陈慧芳 刘毅 刘为中 CHEN Hui-fang;LIU Yi;LIU Wei-zhong(Anqing Medical College,Anhui Anqing 246052;Hefei Infustrial Pharmaceutical Institute Co.,Ltd.,Anhui Hefei 230601,China)
机构地区 安庆医药高等专科学校 合肥医工医药有限公司
出处 《广州化工》 CAS 2022年第5期105-106,112,共3页 GuangZhou Chemical Industry
基金 安徽省高校自然科学研究重点项目(KJ2020A0889,KJ2019A1235) 安徽省高等学校省级质量工程项目(2020jyxm1117)。
关键词 磷酸肌酸钠 磷酸甲酯 超高效液相色谱-串三重四级杆质谱 creatine phosphate sodium trimethyl phosphate ultra-high performance liquid chromatography mass spectrometry
分类号 R917 [医药卫生—药物分析学]
  • 相关文献

参考文献4

二级参考文献48

  • 1卢永昕.慢性心力衰竭的临床评估和治疗原则——2005ACC/AHA慢性心力衰竭治疗指南简介[J].临床心血管病杂志,2005,21(11):691-695. 被引量：24
  • 2ICH Q3A (R2), Impurities in New Drug Substances[ EB/OL]. (2006 - 10-25). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA422. pdf.
  • 3ICH Q3B (R2) Impurities in New Drug Substances [ EB/OL]. (2006 -06-02). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA421. pdf.
  • 4ICH Q3C ( R3 ) Impurities: Guideline for Residual Solvents [EB/OL]. (2005-11). [2014 -03 -31]. http://www, ieh. org/LOB/media/MEDIA423, pdf.
  • 5EMEA. Guideline on the limits of Genotoxic hnpurities [ EB/OL]. (2006 -06 - 28). [2014 -03 -31]. http://www. emea. europa, eu/pdfs/human/swp/519902en, pdf.
  • 6EMEA. Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities, Revision 1 [ S]. (2008 - 06 -26). [2014 -03 -31]. http://www, emea. europa, eu/pdfs/ human/swp/43199407en, pdf.
  • 7FDA. Guidance for Industry Genotoxic and Carcinogenic Impuri- ties in Drug Substances and Products: Recommended Approaches [S]. (2008-11). [2014 -03 -31]. http:// www. fda. gov/ downloads/drugs/guidance complianceregulat-ory information/guidances/ucm079235, pdf.
  • 8ICH. Assessment And Control Of DNA Reactive (Mutagenic) Im- purities In Pharmaceuticals To Limit Potential Carcinogenic Risk[S]. (2013 -02). [2014 -03 -31]. http://www, ieh. org/ product s/guidelines/multi-disciplinary / article/muhidisciplinary- guidelines, html.
  • 9ARIENS E.I. Domestication of chemistry by design of safer chemi- cals: structure-activity relationships[J]. Drug Metab Rev, 1984, 15 ( 3 ) :425 - 504.
  • 10WEISBURGER JH. Environmental Health Perspectives [ J] 1983, 50: 233-245.

共引文献116

广州化工
2022年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部